PuraMed BioScience®, Inc., Launches LipiGesic M Sampling Campaign Targeting Headache Specialists
SCHOFIELD, Wis., Sept. 25, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Headache Specialist Sampling Campaign to place its highly effective migraine medication, LipiGesic M, into the hands of headache specialists across the country. LipiGesic M is an over-the-counter formulation of feverfew and ginger that has been clinically tested and found to provide rapid-relief from migraine headache and associated symptoms.
"LipiGesic M outperforms the top-selling prescription migraine medication," said Russell Mitchell, CEO PuraMed BioScience. "If you consider that there are no reported drug interactions, occurrences of rebound headaches, or serious adverse events, LipiGesic M provides a superior solution for people who suffer with acute migraine at a fraction of the cost of prescription treatments."
The sampling program due to start in October will provide healthcare providers that specialize in the diagnosis and treatment of migraine headache the opportunity to obtain LipiGesic M Patient Starter Kits without cost. The headache specialists can then distribute LipiGesic M samples to their patients who suffer acute migraine pain.
"We know that LipiGesic M works for most sufferers. We have received testimony after testimony of people who have suffered with migraines for 30 or 40 years until they tried LipiGesic M," said Mitchell. "This product has changed the lives of thousands of people who have not found relief with prescription medications. We think our sampling program will be a win-win for everyone."
According to a March 2013 article in the Pharmacy Times titled, Patients Dissatisfied with Migraine Medications, a study conducted by the National Headache Foundation found that 54% of the 500 clinically diagnosed migraine sufferers between the ages of 25 and 45 said their prescription oral migraine medication does not help with every attack.
The article also stated that 3 out of 4 patients told researchers their medications didn't work on migraines that come on quickly or start when a person wakes up in the morning. Over half of patients surveyed (51%) said they were dissatisfied overall with their migraine medications.
"We are pleased to make this program available to healthcare providers," said Mitchell. "LipiGesic M is highly effective in the rapid relief of migraine headache and associated symptoms. A clinical study conducted by three-leading US headache specialists, found that LipiGesic M reduces or completely eliminates migraine pain in at least 64 percent of migraine occurrences. It is safe, fast and is non-drowsy, so a person taking LipiGesic M can be back at full capacity – often in a matter of minutes."
About the Company:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. In addition to its leading product LipiGesic® M, which provides acute relief from migraine headaches; the company also has plans to launch LipiGesic® PM that provides a remedy for insomnia and other sleep disorders as well as LipiGesic® H for common tension headaches.
This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
SOURCE PuraMed BioScience, Inc.